FDA approves the Cyltezo Pen
RIDGEFIELD, Conn. – Boehringer Ingelheim announced Monday that the U.S. Food and Drug Administration (FDA) has approved the Cyltezo Pen, a new autoinjector option for Cyltezo (adalimumab-adbm), an FDA-approved Interchangeable biosimilar to Humira (adalimumab).